Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2

Terminated

• Conditions: Bladder Cancer
• Interventions: Drug: gemcitabine hydrochloride; Drug: irinotecan hydrochloride

• Registration Number: NCT00089128
• Lead Sponsor: Medical University of South Carolina

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with irinotecan works in treating patients with locally advanced or metastatic bladder cancer.

Detailed Description

OBJECTIVES:

Primary

* Determine response in patients with locally advanced or metastatic transitional cell carcinoma of the bladder treated with gemcitabine and irinotecan.

Secondary

* Determine the duration of response in patients treated with this regimen.

* Determine the tolerance to and toxicity of this regimen in these patients.

* Determine the median and progression-free survival of patients treated with this regimen.

OUTLINE: Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with responding disease receive 2 additional courses beyond best response.

Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 24 months.

Study Timeline

• Study Start: 2001-11
• Study First Submitted: 2004-08-04
• Study First Submitted QC: 2004-08-04
• Study First Posted: 2004-08-05
• Primary Completion: 2008-11
• Study Completion: 2008-11
• Results First Submitted: 2018-05-04
• Status Verified: 2018-06
• Results First Submitted QC: 2018-06-13
• Last Update Submitted: 2018-06-13
• Results First Posted: 2018-07-12
• Last Update Posted: 2018-07-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gemcitabine and Irnotecan	irinotecan hydrochloride	-
Gemcitabine and Irnotecan	gemcitabine hydrochloride	-

Primary Outcome Measures

Name	Time	Method
Response Proportion	From registration until time of complete response or partial response

Secondary Outcome Measures

Name	Time	Method
Duration of Response	From registration until disease progression among patients who had at least a partial response.
Progression-free Survival	Time between registration and disease progression or death, whichever comes first.
Frequency of Adverse Events as Assessed by NCI CTC Version 2.0	From the day of first dose until the end of study, an average of 6 months

Trial Locations

Locations (1)

Hollings Cancer Center at Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States